Edition:
United States

Hofseth Biocare ASA (HOFBC.OL)

HOFBC.OL on Oslo Stock Exchange

1.90NOK
4:28am EST
Change (% chg)

kr0.05 (+2.70%)
Prev Close
kr1.85
Open
kr1.84
Day's High
kr1.90
Day's Low
kr1.80
Volume
51,300
Avg. Vol
115,568
52-wk High
kr2.50
52-wk Low
kr1.12

Chart for

About

Hofseth BioCare ASA (HBC) is a Norway-based company, engaged in providing biomarine ingredients for human and animal applications, such as dietary supplements, sport nutrition, functional food and natural health products, animal feed additives and pet food. The Company’s product portfolio comprises Soluble Protein (SPH), which... (more)
No analyst recommendations are available for .

Overall

Beta: -0.33
Market Cap(Mil.): kr431.97
Shares Outstanding(Mil.): 233.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 21.82 15.71
EPS (TTM): -- -- --
ROI: -- 12.49 31.93
ROE: -- 15.66 16.16

BRIEF-Hofseth Biocare Q3 EBITDA loss narrows to NOK 6.3 mln

* Q3 OPERATING REVENUE NOK ‍27.9​ MILLION VERSUS NOK 3.6 MILLION YEAR AGO

Nov 15 2017

BRIEF-Hofseth Biocare signs a NOK 35 mln financing agreement

* REG-HOFSETH BIOCARE ASA: HBC ENTERS INTO A NEW NOK 35M FINANCING AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 07 2017

Norway's Hofseth Biocare sees stronger results ahead as it enters commercial phase -CEO

OSLO, Oct 10 Norwegian biotech firm Hofseth Biocare expects to report stronger results ahead as it enters a new commercial phase, its chief executive officer told Reuters, after reporting higher preliminary figures for the third quarter on Tuesday.

Oct 10 2017

BRIEF-Hofseth Biocare expects to report Q3 revenues of about NOK 28 mln​

* ‍BASED ON PRELIMINARY FIGURES FOR Q3 2017, HOFSETH EXPECTS TO REPORT GROUP REVENUES OF ABOUT NOK 28M FOR QUARTER​

Oct 10 2017

BRIEF-Hofseth Biocare: Roger Hofseth new CEO in HBC

* TOR ERIK S. ANDERSEN HAS CHOSEN TO LEAVE HIS POSITION AS CEO OF HBC

Aug 14 2017

Earnings vs. Estimates